On air · 1 of 3 networks
Kite Pharma
- kitepharma.com
- US
- 4,065 employees
Kite Pharma’s ads on LinkedIn, Meta and Google, recorded by adsrunning. Browse the latest here for free. Sign up free to see all 93. Watch Kite Pharma with Starter to get each new one in your feed.
Watchlist with Starter · $49/mo
| Network | Status | Live ads | Nov 2025LinkedIn activity · 52 weeksOct 2026 | Checked | Next step |
|---|---|---|---|---|---|
| Running | 88 | Checked 29 Oct 2026 | See all 93 ads → | ||
| Meta | Not checked | — | |||
| None recorded | 0 | No ads found on the Google Ads Transparency Center | Checked 2 Oct 2026 | Collect them with the API → |
Kite Pharma has 88 live LinkedIn ads. We recorded no Google ads on 2 Oct 2026.
Latest ads
- LINKEDIN · IMAGESince 10 Sept 2026
Cure in MM: hope, hype, or the new reality? Join our interactive symposium on Friday 25 September at the 23rd IMS Annual Meeting to debate if we are ready to say ‘cure’ in multiple myeloma. #IMS2026 #CellTherapy #CellTherapyTalks
- LINKEDIN · IMAGESince 2 Jun 2026
Heading to the EHA2026 Congress? Join our interactive symposium on Friday 12th June. We’ll be putting patients at the centre, discussing MDT approaches to the CAR T journey. Gain actionable guidance to enhance your practice and improve the lives of patients with DLBCL. #EHA2026 #CellTherapy #CellTherapyTalks
- LINKEDIN · IMAGESince 2 Jun 2026
Heading to the EHA2026 Congress? Join our interactive symposium on Saturday 13th June to explore the evolving CAR T landscape, the role of manufacturing in patient outcomes, and emerging innovations to improve efficiency. It’s more than just cells: speed, reliability, and patient outcomes in CAR T. #EHA2026 #CellTherapy #CellTherapyTalks
- LINKEDIN · IMAGESince 4 May 2026
Heading to COMy 2026, the 12th World Congress on Controversies in Multiple Myeloma? Join our interactive debate on Friday, 15 May, discussing whether earlier use of CAR T vs. non-cellular immunotherapies offers the best path towards better patient outcomes. The best strategy puts patients first. What's yours?
- LINKEDIN · IMAGESince 13 Mar 2026
Heading to the 52nd Annual Meeting of The EBMT? Join our interactive symposium on Sunday 22nd March exploring how to challenge common misconceptions in CAR T-cell therapy for R/R DLBCL. #EBMT26 #CellTherapy #CellTherapyTalks
- LINKEDIN · VIDEORecorded 24 Sept 2026
#KiteNews: At #ASH25, we’re presenting a new pooled analysis highlighting safety and efficacy data and observed quality of life benefits of our treatment in R/R large B-cell lymphoma. Learn more about how this may help further establish a new standard of care: bit.ly/3KLI6S0
6 of 93 adsSign up to see every Kite Pharma ad, filter by format and date, and get alerts on new ones.
See all 93 adsWatch the companies you care about.
Filter every ad by industry, country, format and network, and get alerts when a company you watch starts running new ads.